3693-06-9

Usage

Uses

Used in Pharmaceutical Industry:
2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine is used as a building block or intermediate for the synthesis of various drugs. Its complex structure allows it to be a key component in the development of new medicinal compounds.
Used in Anti-inflammatory and Anti-allergic Applications:
In the medical field, 2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine is used as an anti-inflammatory and anti-allergic agent. Its pharmacological properties make it a candidate for treating conditions that involve inflammation and allergic responses.
Used in Psychiatric and Neurological Treatments:
2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine has also been investigated for its potential role in the treatment of psychiatric disorders and neurological conditions. Its capacity to interact with specific biological targets makes it a promising candidate for further research and development in these therapeutic areas.

Upstream product

• 3693-08-1 3,5-dihydrobenzo[e][1,4]oxazepin-2(H)-one 
• 189940-09-8 2-chloro-N-(2-(hydroxymethyl)phenyl)acetamide 
• 4016-99-3 1-(chloroacetoxy-methyl)-2-(2-chloro-acetylamino)-benzene 
• 2941-78-8 2-Amino-5-methylbenzoic acid 
• 51585-35-4 7-methyl-1,2,3,5-tetrahydrobenzo[E][1,4]oxazepine 
• 5344-90-1 2-Aminobenzyl alcohol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 137975-28-1 1-(4-Nitrobenzoyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine 
• 137975-49-6 1-(4-Aminobenzoyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine 
• 4029-39-4 1-(4-chloro-benzoyl)-1,2,3,5-tetrahydro-benzo[e][1,4]oxazepine 

Relevant academic research and scientific papers

PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents

A series of benzenesulfonamide derivatives were synthesized and evaluated for their anti-proliferative activity and interaction with tubulin. These new derivatives showed significant activities against cellular proliferative and tubulin polymerization. Compound BA-3b proved to be the most potent compound with IC50value ranging from 0.007 to 0.036 μM against seven cancer cell lines, and three drug-resistant cancer cell lines, which indicated a promising anti-cancer agent. The target tubulin was also verified by dynamic tubulin polymerization assay and tubulin intensity assay.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

LXR modulators

A compound of formula I wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein.

Substituted pyridoindoles as serotonin agonists and antagonists

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k

Substituted pyridoindoles as serotonin agonists and antagonists

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k

Substituted pyridoindoles as serotonin agonists and antagonists

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k

Pyridopyrrolobenzoxazine

Compounds of the formula: STR1 where 2 THE R's are the same or different and are H or CH3, and one of them can be C2 -C9 alkyl or phenyl; R1 is hydrogen, C1 -C4 alkyl, C3 -C6 cycloalkyl, C2l -C4 alkoxycarbonyl, or substituted C1 -C4 alkyl where the substituent is C3 -C6 cycloalkyl or phenyl; and Z is H, Cl or CH3 ; and their pharmaceutically suitable salts. The compounds are useful as sedatives; some of them also exhibit antidepressant activity.